WO2001059068A2 - Künstliche knochenchips, verfahren zu ihrer herstellung und ihre verwendung - Google Patents
Künstliche knochenchips, verfahren zu ihrer herstellung und ihre verwendung Download PDFInfo
- Publication number
- WO2001059068A2 WO2001059068A2 PCT/DE2001/000530 DE0100530W WO0159068A2 WO 2001059068 A2 WO2001059068 A2 WO 2001059068A2 DE 0100530 W DE0100530 W DE 0100530W WO 0159068 A2 WO0159068 A2 WO 0159068A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- structures
- cells
- bone chips
- artificial bone
- fibrin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3821—Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3847—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3843—Connective tissue
- A61L27/3852—Cartilage, e.g. meniscus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/46—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
- A61F2/4644—Preparation of bone graft, bone plugs or bone dowels, e.g. grinding or milling bone material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
- A61F2310/00377—Fibrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/56—Fibrin; Thrombin
Definitions
- BFU bone forming units
- cartilage and bone grafts processes for their production and their use in surgery.
- mesenchymal progenitor cells of the periosteum for the treatment of cartilage and especially bone defects in animal models.
- the cells are grown into transplantable precursor tissues in three-dimensional cultures using suitable matrix structures made of fibrin, alginate and polymer scaffold structures (3, 4, 5).
- a carrier material In order to produce a three-dimensional tissue of sufficient size from isolated patient cells, a carrier material must be used, into which isolated and in vitro amplified chondrocytes can be introduced so that they redifferentiate again, form sufficient extracellular matrix and thus for transplantation or as tissue models for the Basic research is available.
- the following requirements are placed on the carrier materials:
- the materials used should be biocompatible, which means that they must neither cause an immunological rejection reaction when used in implants, nor may they impair the normal metabolic activity of the cells due to their presence. Furthermore, the three-dimensional homogeneous distribution of the cells in the carrier and the spatial maturation of the cell tissue should be made possible, for example by holding newly formed matrix molecules in the cell-near area. It would therefore make sense if the material had the largest possible surface for cell adhesion and aggregation of the matrix molecules with a minimal volume and a homogeneous structure and, despite the formability, still had sufficient dimensional stability, for example for use in plastic surgery.
- the carrier material becomes superfluous and should therefore reabsorb, whereby the degradation products in turn must not have any influence on the metabolic activity of the tissue (6).
- In vitro tissue production therefore requires two functional components from the carrier material.
- One component is responsible for the mechanical stability.
- the other ensures a homogeneous distribution of the cells in the structure and supports the formation of the extracellular matrix by the material giving the matrix molecules support. Both functions can be performed by one and the same or by different framework substances (7).
- the resorbable polymer fibers with reproducible properties are e.g. woven into a three-dimensional fleece, are flexible and elastic and can therefore be adapted in shape to the anatomical requirements. They offer a large inner surface with low weight per unit volume and enable three-dimensional colonization by the cells.
- the fibers have the task of a temporary placeholder that dissolves after the ingrowth of the cartilage cells and is replaced by the newly formed extracellular matrix.
- the polymer nonwoven fibers absorb the strain in the first time. As they slowly dissolve, they leave the carrier function to the newly emerging matrix.
- the cells must be insensitive to the degradation products of the fibers. Due to the small amount of material, however, comparatively few degradation products arise, which then have to be removed from the tissue formed.
- the degradation of the polymers follows the following scheme: First, the material swells up due to water retention. Here, e.g. the hydrogen bonds that determine the spatial structure of the polymers are broken. Then the polymer chains break apart. The carrier loses its mechanical stability. Finally, the low-molecular fragments are broken down into carbon dioxide and water via the body's own metabolic pathways (8).
- the disadvantage of these polymer fibers compared to gels, for example, is that the spatially homogeneous distribution of the cartilage cells is difficult.
- the cells must also be fixed in the fleece, since they endeavor to sink downwards.
- the fixation can be done either by directly adhering to the Chondrocytes on the fibers, e.g. B. with the aid of adhesion factors, or by a slight crosslinking of the cell suspension with gel-like substances such as agarose, fibrin or hyaluronic acid, the latter being preferred in favor of a homogeneous distribution of the cells in the carrier.
- gel-like substances such as agarose, fibrin or hyaluronic acid, the latter being preferred in favor of a homogeneous distribution of the cells in the carrier.
- suitable gel-like substances also makes it possible to increase the average distance between the fibers, so that the total amount of the resorbable polymer per tissue volume is further reduced.
- the fibers therefore mainly serve as tissue scaffolds and less for three-dimensional cell distribution.
- the cells therefore do not have to bind to the fibers.
- This modeled ear construct with human chondrocytes was implanted subcutaneously in a mouse with a weakened immune system (without thymus) and initially supported from the outside. It kept its shape. Type II collagen was found in the newly formed tissue as a marker for hyaline cartilage (14).
- collagen matrix which is made from type I bovine collagen and therefore naturally has poorly reproducible properties (15). It offers very good cell binding capabilities. Cells that have been cultivated in a collagen matrix look round and show weak collagen production when proteoglycan synthesis is weak, which was demonstrated by the incorporation of proline. Since the collagen synthesis is feedback-controlled, the collagen of the matrix could also be considered as a substrate. Becomes collagen implanted without cells in a joint cartilage, it grows. The newly formed tissue looks like fibrous tissue and contains a lot of collagen but little proteoglycans. However, the latter are of great importance for pressure elasticity (16).
- the gels do not have sufficient mechanical stability.
- Hydrogels are based on various structural and physicochemical properties of the extracellular matrix, which in principle is also a gel made of hyaluronic acid and proteoglycans, in which supporting collagen fibers are embedded.
- Agarose gels are widely used to research chondrogenesis. The agarose gel allows a large distance between the cells so that matrix molecules have space to aggregate (17, 18). However, large molecules remain, e.g. Aggrecan, in the pericellular area, so that an intercellular matrix cannot be formed (19).
- Fibrin gel has been used in surgical medicine for 20 years. It meets all the necessary requirements on the part of biocompatibility and infection security.
- a PGA / PLA copolymer fleece filled with fibrin gel enables a homogeneous three-dimensional cell distribution with an average cell spacing of 50 ⁇ m.
- the chondrocytes have a round shape.
- the fleece structure largely dissolves and the fragments of the fleece network are evenly embedded in the extracellular cartilage matrix.
- type II collagen can be detected with an antibody test. Type I collagen was not found. The controversial discussion about infection safety of industrially manufactured fibrin preparations is not necessary when using autologous fibrin (DE 198 24 306).
- Alginate is an immobilization matrix in which the chondrocytes retain their phenotype over a long cultivation period of up to eight months.
- Adult human chondrocytes form an extracellular matrix in the alginate gel.
- Alginate beads with autologous chondrocytes implanted subcutaneously (mini-pig) show a distinct tissue after six weeks, covered with a fibrous capsule. Approximately 30% to 40% of this tissue was cartilage (20).
- the alginate beads can also be combined with a hyaluronic acid gel or a fibrin gel. Then you get significantly more cells through the hyaluronic acid in the bead.
- fibrin also leads to a strong increase in the number of cells (21). However, it still needs to be clarified to what extent the strong proliferation includes the desired matrix formation.
- alginate as an implant carrier appears questionable, since the immunological behavior of the plant material and the security against infection are still unclear and problematic.
- hyaluronic acid By crosslinking the hyaluronic acid chains, hyaluronic acid (HA) becomes a useful carrier material. Depending on the type of crosslinking reaction, HA fibers or HA gels are obtained.
- the group around Aigner used e.g. non-woven fibers from HA-benzyl ester (J. Aigner, et al., Cartilage tissue engineering with novel nonwoven structured biomaterial based on hyaluronic acid benzyl ester. J. Biomed Mater Res. 42, 172-181, (1998)). These fibers completely degrade after two months by spontaneous hydrolysis of the ester bond at 37 ° C.
- tissue engineering Another approach in tissue engineering is to stimulate tissue regeneration as a whole or at least to differentiate the cells, for example by adding growth factors.
- factors of the TGF-ß superfamily Transforming Growth Factor-beta
- TGF-ß superfamily Transforming Growth Factor-beta
- genes from the TGF-ß family can be introduced into part of the cells to improve maturation, but also around the tissue To protect against renewed destruction, for example in a chronically inflamed joint (28, 29, 30, 31).
- release systems that is, the temporary release of factors from resorbable microparticles, for example to stabilize a transplant during the critical phase of healing.
- direct tissue regeneration without cells can only be used using growth factors and biomaterials (32).
- the invention is based, largely prefabricated and stable bone or. Provide cartilage replacement tissue.
- the task was solved by producing artificial bone chips.
- the artificial bone chips according to the invention represent flexible, resorbable, modular elements with cells and / or growth factors and are suitable for the practical use of bone and cartilage tissue engineering in surgery. They can be used to treat or fill tissue defects of various spatial dimensions.
- the artificial bone chips consist of bioresorbable or biocompatible carrier materials and / or framework structures. They are characterized by the fact that they consist of combinations of osteogenic cells and factors cross-linked by fibrin or hydrogel, which are formed into mutually attachable geometric bodies. They consist of porous resorbable or non-resorbable framework structures, the framework structures having plastic and / or elastic components.
- the individual modules can be connected to one another in different ways. They have a profile structure or are a closed hollow structure.
- the chip material itself is porous in such a way that cells that are cross-linked by biopolymers (e.g. fibrin) can be distributed or introduced into the material.
- biopolymers e.g. fibrin
- calcium phosphate e.g. alpha- or beta-tri-calcium phosphate
- Zeil solution can also be added to the Zeil solution.
- the shape and connections of the bone chips ultimately create a third level of the framework structure.
- the levels are: 1. Cell crosslinking through fibrin or hydrogel
- the networked cells are stabilized in a fiber structure and
- the fiber frameworks are assembled as modular hollow and profile bodies to form a macro framework.
- the modules can either be cultured in vitro with cells or immediately osteogenic cells or factors are added by injection into hollow bodies / cavities before or after implantation.
- the artificial bone chips are modular bone replacement structures based on bioresorbable or biocompatible carrier materials, which can be combined - filled, soaked or coupled - with osteogenic cells or factors. They consist of porous resorbable or non-resorbable framework structures. They are preferably used in suitable shapes, for example in the form of cubes or cuboids (for example in mm 2x2x2 to 4x4x2 or 10x5x2). Polygonal shapes are also possible, e.g. hexagon / honeycomb-like area 1 cm 2 ). They can also be spherical, lenticular or band / band-like. According to an advantageous embodiment, the shape of the artificial bone chips is tubular / cylindrical u- or v-profiles or hollow profiles.
- the framework structures can be support structures, ie fiber structures or fleece structures, or lattice structures, woven structures, foam structures, cotton structures or structures with interconnecting porosity, which are produced from plastic and elastic components.
- the fiber structure - wool or fleece - contains elastic, additionally resorbable or non-resorbable, plastic, deformable fibers, tapes or support wires.
- the support structure of the bone chips is multi-phase and consists of two or more of the plastic, elastic and solid phases.
- the artificial bone chips according to the invention can be plugged or hooked together via surface profiles - for example tongue and groove, serrations, tips, holes, hooks, eyes or Velcro fasteners.
- the artificial bone chips are largely or completely closed hollow structures with permeable walls that can be filled with injections with osteogenic bioactive factors or cells.
- FGF fibroblast growth factor
- TGF transforming growth factor
- BMP bone morphogenetic protein
- periosteal cells mesenchymal stem cells or osteoprogenitor cells
- the permeability of the wall structures of the hollow chips according to the invention is achieved either by the fiber or lattice structure or by additionally applied absorbable or non-absorbable permeable membranes.
- different bone chips or hollow structures are filled with different factors or cells.
- Artificial bone chips can be applied to endoprostheses in a comparable or similar way to a Velcro fastener.
- the bone replacement module according to the invention can be combined with other artificial tissue structures, for example cartilage replacement (for example, osteochondral graft).
- the bone chips are connected to one another and / or to the surrounding tissue by fibrin glue, acrylate glue or lactide glue.
- fibrin glue acrylate glue or lactide glue.
- autologously produced fibrin or thrombin or recombinant fibrin or thrombin can also be used.
- Porous bone chips can be mixed with gel substances (fibrin, alginate, hyaluronic acid, collagen,
- the bone chips with bioactive elements (cells and / or factors), which can be combined with gel substances, are precultivated in vitro in culture media.
- the method according to the invention for producing the artificial bone chips consists of cells or factors being crosslinked by fibrin or hydrogel, and the crosslinked cells being stabilized in scaffold structures, in particular in a fiber scaffold, and being formed into mutually attachable geometric bodies.
- the fiber frames are then assembled as modular hollow and profile bodies to form a macro frame.
- the chips are cultivated in vitro with cells or osteogenic cells or factors are added by injection into hollow bodies / cavities immediately before or after the implantation.
- Another feature of the method is that the carrier materials and / or framework structures are combined - filled, soaked and / or coupled - with osteogenic cells or factors.
- the cells or factors can be precultivated.
- the features of the invention also emerge from the description, the individual features representing advantageous protective designs, individually or in combination in the form of combinations, for which protection is requested with this document.
- the combination consists of known (carrier materials, carrier structures) and new elements (modular bone replacement structures, artificial bone chips) that mutually influence each other and result in an advantage (synergistic effect) and the desired success in their new overall effect, which lies in the fact that now largely prefabricated and stable cartilage or bone replacement tissues are available.
- the use of the new artificial bone chips according to the invention is in the field of surgery, especially in the treatment of bone defects, for example after broken bones, Bone tumors, bone cysts or in the periprosthetic area (around prostheses). It also affects the treatment of chronic joint diseases.
- the use of the chips (modules) according to the invention relates to the production of osteochondral cartilage-bone grafts or modelable cartilage or bone grafts. It is also aimed at repairing defects in articular cartilage or articular cartilage surfaces.
- the use of the new artificial bone chips according to the invention further relates to the production of complex vital bioprostheses. It is also aimed at
- the artificial bone chips are combined with gel substances - fibrin, alginate, hyaluronic acid, collagen or agarose.
- Two stackable chips are each filled with a fibrin gel cell suspension or hydrogel cell suspension.
- Periosteal cells or mesenchymal connective tissue precursor cells are used as cells.
- One chip is cultivated with osteogenic medium, the second with chondrogenic medium.
- the elements are inserted into each other and glued with fibrin or lactide glue.
- Example 3 Production of modelable cartilage or bone grafts:
- the fiber structure consists of thin resorbable fibers made of PGLA and additional plastically formable wires or wire mesh.
- the cell-fiber construct is then manually adapted to the surgical requirements.
- Figure 1 left: cell distribution depending on fiber distribution and cell attachment; right: cells distributed by cross-linking gel components, this allows larger distances between the scaffold fibers.
- Figure 2 Module-like bone replacement structures (artificial bone chips) made of porous resorbable or non-resorbable framework structures are interconnected
- FIG. 3 Mesenchymal cells are distributed in a fiber structure (A) by fibrin crosslinking. Additionally introduced plastically formable wires (B) or a wire mesh allow a defined shape / mechanical stability according to the surgical requirements.
- FIG. 4 Osteochondral graft: A: Cartilage graft consisting of chondrogenic
- B Bone graft consisting of osteogenic cells in a carrier structure (pre-cultivated under osteogenic culture conditions). The connection is made via interconnecting
- Sittinger M Bujia J: Process for producing an implant from cell cultures. (1994: DE patent 4306661.5). 3. Sittinger M, Schultz O, Burmester GR, Häupl T: Artificial tissues, methods for the production and the use thereof. U.S. Patent 5,932,459.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01911447A EP1263929A2 (de) | 2000-02-08 | 2001-02-07 | Künstliche knochenchips, verfahren zu ihrer herstellung und ihre verwendung |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10006822A DE10006822A1 (de) | 2000-02-08 | 2000-02-08 | Künstliche Knochenchips, Verfahren zu ihrer Herstellung und ihre Verwendung |
DE10006822.7 | 2000-02-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001059068A2 true WO2001059068A2 (de) | 2001-08-16 |
WO2001059068A3 WO2001059068A3 (de) | 2002-02-14 |
Family
ID=7631048
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2001/000530 WO2001059068A2 (de) | 2000-02-08 | 2001-02-07 | Künstliche knochenchips, verfahren zu ihrer herstellung und ihre verwendung |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1263929A2 (de) |
DE (1) | DE10006822A1 (de) |
WO (1) | WO2001059068A2 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569172B2 (en) | 1996-08-30 | 2003-05-27 | Verigen Transplantation Service International (Vtsi) | Method, instruments, and kit for autologous transplantation |
US6592599B2 (en) | 1996-08-30 | 2003-07-15 | Verigen Transplantation Service International (Vtsi) | Method, instruments, and kit for autologous transplantation |
DE10241572A1 (de) * | 2002-09-07 | 2004-03-25 | Werner Scholz | Stütz- oder Halteteil zum Einbringen in ein Knochenteil |
CN107405201A (zh) * | 2015-01-09 | 2017-11-28 | 孚美公司 | 刚性的节段化柔性锚件 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10222896A1 (de) * | 2002-05-23 | 2003-12-11 | Biotissue Technologies Ag | Verfahren zur Herstellung eines dreidimensionalen und flächigen Gewebetransplantats |
EP1457129B1 (de) * | 2003-03-13 | 2004-11-10 | Mattes & Ammann KG | Verfahren zum Herstellen von Klettverschlüssen und Klettverschluss selbst |
DE102005030614B4 (de) | 2005-06-30 | 2014-05-08 | Biotissue Ag | Zellfreies Transplantat, dessen Verwendung, Verfahren zu dessen Herstellung, dabei hergestellte Matrix mit Gel und Verfahren zur Herstellung dieser Matrix mit Gel |
DE102006047346A1 (de) | 2006-10-06 | 2008-04-10 | Transtissue Technologies Gmbh | Matrix-Gel-Transplantat ohne Zellen |
DE102015107599A1 (de) * | 2015-05-13 | 2016-11-17 | Heraeus Medical Gmbh | Flächiges Knochenersatzmaterial und Verfahren zur Herstellung eines porösen Körpers |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003160A1 (en) * | 1994-07-26 | 1996-02-08 | Children's Medical Center Corporation | Fibrin-cell suspension for construction of new tissue |
WO1999048541A1 (en) * | 1998-03-26 | 1999-09-30 | University Of Pittsburgh | Assembled scaffolds for three-dimensional cell culturing and tissue generation |
WO1999055252A1 (en) * | 1998-04-24 | 1999-11-04 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
-
2000
- 2000-02-08 DE DE10006822A patent/DE10006822A1/de not_active Ceased
-
2001
- 2001-02-07 EP EP01911447A patent/EP1263929A2/de not_active Withdrawn
- 2001-02-07 WO PCT/DE2001/000530 patent/WO2001059068A2/de active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003160A1 (en) * | 1994-07-26 | 1996-02-08 | Children's Medical Center Corporation | Fibrin-cell suspension for construction of new tissue |
WO1999048541A1 (en) * | 1998-03-26 | 1999-09-30 | University Of Pittsburgh | Assembled scaffolds for three-dimensional cell culturing and tissue generation |
WO1999055252A1 (en) * | 1998-04-24 | 1999-11-04 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569172B2 (en) | 1996-08-30 | 2003-05-27 | Verigen Transplantation Service International (Vtsi) | Method, instruments, and kit for autologous transplantation |
US6592599B2 (en) | 1996-08-30 | 2003-07-15 | Verigen Transplantation Service International (Vtsi) | Method, instruments, and kit for autologous transplantation |
US6592598B2 (en) | 1996-08-30 | 2003-07-15 | Verigen Transplantation Service International (Vtsi) | Method, instruments, and kit for autologous transplantation |
US6599300B2 (en) | 1996-08-30 | 2003-07-29 | Verigen Transplantation Service International (Vtsi) | Method, instruments, and kit for autologous transplantation |
US6599301B2 (en) | 1996-08-30 | 2003-07-29 | Verrgen Transplantation Service International (Vtsi) | Method, instruments, and kit for autologous transplantation |
US7048750B2 (en) | 1996-08-30 | 2006-05-23 | Verigen Ag | Method, instruments, and kits for autologous transplantation |
US7137989B2 (en) | 1996-08-30 | 2006-11-21 | Verigen Ag | Method, instruments, and kit for autologous transplantation |
DE10241572A1 (de) * | 2002-09-07 | 2004-03-25 | Werner Scholz | Stütz- oder Halteteil zum Einbringen in ein Knochenteil |
DE10241572B4 (de) * | 2002-09-07 | 2007-02-08 | Werner Scholz | Stütz- oder Halteteil zum Einbringen in ein Knochenteil |
CN107405201A (zh) * | 2015-01-09 | 2017-11-28 | 孚美公司 | 刚性的节段化柔性锚件 |
US10485664B2 (en) | 2015-01-09 | 2019-11-26 | Formae, Inc. | Rigid segmented flexible anchors |
US11793646B2 (en) | 2015-01-09 | 2023-10-24 | Formae, Inc. | Rigid segmented flexible anchors |
Also Published As
Publication number | Publication date |
---|---|
EP1263929A2 (de) | 2002-12-11 |
DE10006822A1 (de) | 2001-08-23 |
WO2001059068A3 (de) | 2002-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69534038T2 (de) | Vorrichtung und verfahren zum in-vivo-züchten von verschiedenen gewebezellen | |
DE60207198T2 (de) | Transplantate für die wiederherstellung von osteochondralen schäden | |
Jahangirian et al. | A review of using green chemistry methods for biomaterials in tissue engineering | |
DE60019354T2 (de) | Verfahren zur Knorpelgeweberegeneration | |
Tabesh et al. | The role of biodegradable engineered scaffolds seeded with Schwann cells for spinal cord regeneration | |
DE69828519T2 (de) | Membran zur gesteuerten regeneration von gewebe | |
Thomson et al. | Biodegradable polymer scaffolds to regenerate organs | |
DE69432865T2 (de) | Implantierbare prothese, kit und vorrichtung zu deren herstellung | |
DE60006356T2 (de) | Hochmineralisierte osteogene schwammzusammensetzungen und ihre verwendung | |
EP1523342B1 (de) | Strukturierte komposite als matrix (scaffold) fur das tissue engineering von knochen | |
Tebyanian et al. | Effects of collagen/β-tricalcium phosphate bone graft to regenerate bone in critically sized rabbit calvarial defects | |
WO2000032251A1 (de) | Poröse kompositmatrix, deren herstellung und verwendung | |
WO2001059068A2 (de) | Künstliche knochenchips, verfahren zu ihrer herstellung und ihre verwendung | |
WO2011018520A2 (de) | Verfahren zur herstellung eines biokompatiblen und bioabbaubaren kompositmaterials, das danach erhältliche kompositmaterial sowie dessen verwendung als medizinprodukt | |
Alvites et al. | Biomaterials and cellular systems at the forefront of peripheral nerve regeneration | |
DE10220368A1 (de) | Versteiftes Implantat | |
DE102009018640A1 (de) | Implantat und therapeutische Zusammensetzung zur Behandlung von Schäden und/oder Erkrankungen im Bereich des menschlichen und/oder tierischen Stütz- und Bewegungsapparates | |
DE112016001386B4 (de) | Kohlenstoffpartikel und Komposite derselben für die Regeneration von Skelettmuskelgewebe und Weichgewebe | |
DE602004010307T2 (de) | Verwendung von polysulfatiertem alginat in zellmatrix | |
WO2004042038A1 (de) | Verfahren zur behandlung von erkranktem,degeneriertem oder geschädigtem gewebe unter verwendung von in vitro hergestelltem dreidimensionalem gewebe in kombination mit gewebezellen und/oder exogenen faktoren | |
DE10339953B3 (de) | Implantatmaterial für den Knochen-Knorpel-Ersatz und seine Verwendung | |
WO2006010547A2 (de) | Bioresorbierbares material zur füllung von knochendefekten | |
DE19917696A1 (de) | Mittel für die Herstellung biologischer Teile mit einem Wirkstoffkomplex und für diesen geeigneten Trägermaterialien | |
Robertson et al. | Bioactive impact of manuka honey and bone char incorporated into gelatin and chitosan cryogels in a rat calvarial fracture model | |
RU2385727C1 (ru) | Биосовместимая композиция для восполнения (лечения) частичных и полных дефектов хрящевой и костной ткани и способ получения биосовместимой композиции для восполнения (лечения) частичных и полных дефектов хрящевой и костной ткани |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001911447 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001911447 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |